SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Annual Wellness Visit, Subsequent — Ella Fitzgerald — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientElla Fitzgerald
Date of birth1917-04-25
IdentifiersMRN HR-ML029-SYN-TD; SSN (made up) 000-29-3640
Document date1987-06-15
AuthorOdessa Whitlow, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Subsequent annual wellness visit. [S]

History of Present Illness

Ms. Fitzgerald is a 70-year-old singer with type 2 diabetes and peripheral artery disease, macular edema in the right eye, and coronary bypass surgery last year, who comes for her subsequent annual wellness visit five weeks after her first visit and three weeks after her vascular surgery consultation. Since glipizide was stopped and glargine was moved to the morning, her continuous glucose monitor has shown one reading of 66 mg/dL, on a travel day when lunch was late, and none below 54. She started low-dose rivaroxaban with her aspirin after the consultation and has had no bleeding. She has had two weeks of the supervised walking program and can already walk a little farther. She had her first injection in the right eye two weeks ago and saw the podiatrist last week, who pared the calluses and measured her for low-heeled stage shoes. She has a two-week run of concerts starting next month. [S]

ElementDetail
VisitSubsequent annual wellness visit
GlucoseOne reading of 66 mg/dL on a travel day; none below 54 mg/dL
New since intakeEmpagliflozin, glargine in the morning, rivaroxaban 2.5 mg twice daily, continuous glucose monitor
Walking programSupervised exercise three times a week for two weeks
Eye and foot careFirst right-eye injection two weeks ago; podiatry last week
Functional statusIndependent; walks about two blocks; uses a wheelchair in large airports

Health risk assessment. Completed with a medical assistant reading the questions aloud, because of her right-eye vision, and reviewed with her by Dr. Whitlow. [S]

DomainFinding
Self-rated healthGood, and better than last year after the heart surgery
PsychosocialHer music and audiences give her purpose; her band and road manager are close; no loneliness
BehavioralNo tobacco; alcohol rarely; meals irregular on tour; walking program three times a week; sleeps about seven hours, later on show nights
Activities of daily livingIndependent in bathing, dressing, eating, toileting, and transfers
Instrumental activities of daily livingManages her medicines with a weekly organizer; her road manager handles travel; does not drive
Home safetySmoke detectors working; rugs secured; good lighting; no firearm
FallsNo falls in the past year; careful on stage steps
Hearing and visionNo hearing concern; right-eye vision blurred, under treatment; lens implants in both eyes
BladderNo incontinence; urinates a little more since empagliflozin
MemoryNo concerns; learns new songs easily

Review of Systems

SystemResultFinding
ConstitutionalNegativeWeight down 0.6 kg; no fever or fatigue
EyesPositiveRight-eye blur, slightly better since the injection; no eye pain or redness
Ears, nose, mouth, and throatNegativeNo hearing change; voice strong
CardiovascularPositiveCalf cramping after about two blocks; no chest pain, breathlessness, palpitations, or ankle swelling
RespiratoryNegativeNo cough or breathlessness
GastrointestinalNegativeNo nausea, diarrhea, or blood in the stool
GenitourinaryNegativeNo burning, itching, or discharge on empagliflozin
MusculoskeletalNegativeNo joint pain limiting walking
IntegumentaryNegativeNo foot sores or blisters on daily checks
NeurologicalNegativeNo numbness, tingling, or weakness
PsychiatricNegativeMood good; PHQ-2 score 0
EndocrineNegativeNo shakiness or sweating since the plan changed, apart from one mild low on a travel day
HematologicNegativeNo bruising, nosebleeds, or bleeding gums on rivaroxaban and aspirin

13 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1000 mg oral tablet, one tablet by mouth twice daily with mealsOne tablet by mouth twice daily with breakfast and the evening mealOral route1977-03-01activeS
Glipizide 10 mg oral tablet, one tablet by mouth twice daily before mealsOne tablet by mouth twice daily before breakfast and the evening mealOral route1982-09-01 to 1987-05-11completedS
Insulin glargine 100 units/mL pen, 30 units under the skin at bedtime30 units at bedtimeSubcutaneous route1984-04-01 to 1987-05-11completedS
Insulin glargine 100 units/mL pen, 24 units under the skin each morning24 units each morning, at the same clock time on tour, with written time-zone adjustmentsSubcutaneous route1987-05-11activeS
Atorvastatin 40 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1986-06-02 to 1987-05-11completedS
Atorvastatin 80 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1987-05-11activeS
Aspirin 81 mg delayed-release oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1986-06-02activeS
Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1986-06-02activeS
Empagliflozin 10 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morning; hold on days she cannot eat or drink normally and before surgeryOral route1987-05-11activeS
Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucoseOne spray into one nostril if she cannot safely swallow during a low glucose; may repeat once after 15 minutes with a new device; call 911Nasal route1987-05-11activeS
Rivaroxaban 2.5 mg oral tablet, one tablet by mouth twice daily with aspirin 81 mgOne tablet by mouth twice daily, with aspirin 81 mg once dailyOral route1987-05-26activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1987-06-15Body height165cmS
1987-06-15Body weight83.4kgS
1987-06-15Body mass index (BMI) [Ratio]30.6kg/m2S
1987-06-15Systolic blood pressure124mm[Hg]S
1987-06-15Diastolic blood pressure68mm[Hg]S
1987-06-15Heart rate60/minS
1987-06-15Respiratory rate16/minS
1987-06-15Body temperature36.6CelS
1987-06-15Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1987-06-15Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
1987-06-15Total score [Mini-Cog]5{score}S
1987-06-15Total score [AUDIT-C]1{score}S

Physical Exam

Vital signs recorded on 1987-06-15; see the Vital Signs section. [S]

SystemFinding
ConstitutionalWell and animated; weight 83.4 kg, BMI 30.6; blood pressure 124/68
EyesLens implants in both eyes; injection site in the right eye healed; no redness
Ears, nose, and throatWhispered voice heard in both ears
CardiovascularRegular rhythm; healed sternotomy scar; no murmur; femoral pulses present; right foot pulses absent and left faint, as before
RespiratoryClear to auscultation bilaterally
FeetCalluses pared; hammer toes; skin intact; no ulcer; protective sensation intact
MusculoskeletalTimed Up and Go 11 seconds without an aid
NeurologicalOriented; recall and reasoning normal; Mini-Cog 5 of 5
PsychiatricEuthymic and engaged
SkinNo suspicious lesions on the exposed skin

Problems

ProblemClinical statusVerificationCodeProvenance
Type 2 diabetes mellitus with peripheral artery disease: cramping in both calves after about one and a half blocks of walking, worse on the right, easing within minutes of rest; no rest pain, wounds, or color change. Resting ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55; dorsalis pedis and posterior tibial pulses absent on the right and faint on the left. A1c 8.6% on metformin, glipizide and glargine, with low glucose readings (to 52 mg/dL) after late performances. Foot: protective sensation intact to the 10-g monofilament at all sites and to vibration; callus under the second metatarsal heads; hammer toes of the second and third toes; no ulcer (IWGDF risk category 2). Synthetic modern episode linked to her documented diabetes and its circulatory complicationsactiveconfirmed E11.51S — Synthetic modern diagnosis; the type of diabetes was not made public and is synthetic.
Moderate nonproliferative diabetic retinopathy with center-involving diabetic macular edema in the right eye (best-corrected acuity 64 letters, about 20/50) and moderate nonproliferative retinopathy without macular edema in the left eye (81 letters); lens implants in both eyes from earlier cataract surgery. Synthetic modern episode linked to her documented diabetic eye problemsactiveconfirmed E11.3311S — Synthetic modern eye diagnosis on retinal imaging and optical coherence tomography in the clinic; the left eye is described in the display.
Coronary artery disease after five-vessel coronary bypass surgery last year, with an intensive care stay; no angina now; on aspirin, a statin, and metoprolol. Synthetic modern episode linked to her documented heart surgeryactiveconfirmed I25.10S — Synthetic modern coding of her documented heart surgery; bypass grafts are described in the display.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Influenza vaccineDueHigh-dose or adjuvanted vaccine due in the autumn
COVID-19 vaccineDueRecommended at 65 and older; due in the autumn
Pneumococcal vaccineCompleted todayPCV20 given today; no further doses needed
Recombinant zoster vaccineDueDose 1 at the autumn review with the influenza vaccine, dose 2 two to six months later
RSV vaccineDueRecommended at 60 to 74 with diabetes complications and heart disease; one dose before the respiratory season
Tetanus, diphtheria, and pertussisUp to dateTdap four years ago
Breast cancer screeningOrderedMammogram every two years to 74; last one two years ago
Colorectal cancer screeningUp to dateNormal colonoscopy four years ago; next due at ten years, with the decision individualized after 75
Osteoporosis screeningOrderedBone density scan recommended at 65 and older; none on record
Hepatitis C screeningOrderedOne-time screening for adults through 79; added to the three-month tests
Depression screeningCompleted todayPHQ-2 score 0
Alcohol misuse screeningCompleted todayAUDIT-C score 1
Cognitive assessmentCompleted todayMini-Cog 5 of 5
Falls preventionCompleted todayTimed Up and Go 11 seconds; no falls; exercise program under way
Diabetic eye examinationUp to dateRetina clinic treating the right macular edema; both eyes examined
Diabetic foot examinationCompleted todayNo ulcer; podiatry every three months
Kidney screeningUp to dateeGFR 67 and urine albumin-creatinine ratio 18 mg/g at intake
Lung cancer and abdominal aortic aneurysm screeningNot indicatedShe has never smoked

Immunizations given today: Pneumococcal conjugate vaccine (PCV20) [S]

Guideline basis: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026); Medicare Wellness Visits (Medicare Learning Network) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); Adult Immunization Schedule by Age (2026)

Follow-up: Mammogram and bone density scan to be scheduled between tour dates. Three-month review in eight weeks with A1c, lipids, kidney tests, and hepatitis C screening. Next annual wellness visit in one year. Next scheduled visit 1987-08-10: three-month review: A1c, lipids, walking program, eye treatment, and foot care. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 18 minutes, with her consent. She reviewed the written directive she made before her heart surgery and confirmed a health care agent, recorded in the confidential part of the chart and not named here. She said that what matters most to her is to keep singing and travelling for as long as she can, and to keep her sight. She will review the directive yearly. [S]